Stanford’s EBS Study #2: Computational Drug Repurposing for Epidermolysis Bullosa Simplex

Study Site: Stanford

About the Study

Study 2 is a drug discovery trial titled “Computational Drug Repurposing for Epidermolysis Bullosa Simplex (EBS).” For this study, Stanford is recruiting individuals with EBS and healthy volunteers of all ages. This study will compare gene expression differences between blistered and non-blistered skin from individuals with EBS as well as normal skin from healthy individuals. State of the art computational analysis will be performed to help identify new drugs that might help EB wound healing and reduce pain. Stanford will specifically focus on drugs that have already been approved for treatment of other dermatologic or non-dermatologic diseases and therefore can be repurposed for EBS. Drug development is a very expensive process that can take decades. Drug repurposing on the other hand, significantly reduces the cost of and shortens the amount of time that is needed to bring effective treatments to clinical use. To date, there is no specific treatment targeting the physiology and immunologic response in EB patients during wound healing. Repurposing existing medications on the market would ensure that EB patients have rapid access to more treatments that can improve their quality of life. This is a novel approach in therapeutic discovery for genetic diseases that might be beneficial for other patients in the future.

If you have any questions or are interested in these study, please email pediatricDermStudy [at] stanford [dot] edu, contact Elidia Tafoya at (650) 724-1982 or etafoya [at] stanford [dot] edu, or contact Monica Martin at (650) 723-0636 or momartin [at] stanford [dot] edu.